Boosting a protein to protect brain cells in Alzheimer's disease
Increasing synaptic PSD-95, a neuroprotection approach against Alzheimer's disease
This study is looking at how a protein called PSD-95 can help protect brain cells from damage in Alzheimer's disease, and it’s testing a new drug that might boost this protein to keep your brain healthier for longer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Diego NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project ID | NIH-11080306 on NIH RePORTER |
What this research studies
This research investigates the role of PSD-95, a protein crucial for maintaining synaptic health, in the context of Alzheimer's disease. It aims to understand how increasing levels of PSD-95 can protect brain cells from damage caused by amyloid beta, a peptide linked to Alzheimer's. The researchers will explore a novel drug that inhibits the enzyme responsible for removing PSD-95 from synapses, potentially leading to new therapeutic strategies. Patients may benefit from insights into how enhancing PSD-95 could slow down or prevent synaptic loss associated with Alzheimer's.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those at risk of developing it.
Not a fit: Patients with other forms of dementia unrelated to Alzheimer's may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that protect brain function and slow the progression of Alzheimer's disease.
How similar studies have performed: Previous studies have shown promising results in enhancing synaptic health through similar approaches, indicating potential for success in this novel investigation.
Where this research is happening
La Jolla, United States
- University of California, San Diego — La Jolla, United States (Active)
Researchers
- Principal investigator: Dore, Kim Bohemie — University of California, San Diego
- Study coordinator: Dore, Kim Bohemie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.